Last reviewed · How we verify
Stevens-Johnson syndrome — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Prelone | prednisolone | Generic (originally Schering) | Glucocorticoid (corticosteroid) | Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 | 1955-01-01 | |
| Acthar Gel | CORTICOTROPIN | Mallinckrodt Ireland | Adrenocorticotropic Hormone [EPC] | Melanocyte-stimulating hormone receptor | 1950-01-01 | |
| prednisolon | prednisolon | Hannover Medical School | Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Schering) · 1 drug in Stevens-Johnson syndrome
- Hannover Medical School · 1 drug in Stevens-Johnson syndrome
- Mallinckrodt Ireland · 1 drug in Stevens-Johnson syndrome
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Stevens-Johnson syndrome:
- Stevens-Johnson syndrome treatment updates — RSS
- Stevens-Johnson syndrome treatment updates — Atom
- Stevens-Johnson syndrome treatment updates — JSON
Cite this brief
Drug Landscape (2026). Stevens-Johnson syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/stevens-johnson-syndrome. Accessed 2026-06-10.
Related
- Stevens-Johnson syndrome full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing